Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis.

Authors :: Flohr C
Irvine AD
Cork MJ
Simpson EL
Wollenberg A
Deleuran M
Praestgaard A
Thomas RB
Rossi AB
Source :: The British journal of dermatology [Br J Dermatol] 2023 Jul 17; Vol. 189 (2), pp. 238-240.
Publication Year :: 2023
Abstract: Competing Interests: Conflicts of interest See Appendix S1 for full Conflicts of Interest list.

Subjects :: Humans
Child
Quality of Life
Antibodies, Monoclonal, Humanized therapeutic use
Patient Reported Outcome Measures
Treatment Outcome
Severity of Illness Index
Double-Blind Method
Dermatitis, Atopic drug therapy
Dermatitis, Atopic diagnosis

Full Text Access

Tools